HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

Drug Channels News Roundup, May 2026: My $0.02 on Optum Rx's Transparency, Must-Read 340B History, PBM Unbundling Update, PA Delays, and Vegas Fun

By Adam J. Fein, Ph.D.Summer unofficially kicked off last weekend. So fire up the grill and enjoy these noteworthy delicacies, seared to perfection on the Drug Channels barbeque: Why Optum Rx Is Accelerating Its Transparency Strategy The Most Important 340B Paper You'll Ever Read Blue Shield of Cali

By Drug Channels · May 27, 2026 · via Drug Channels

This is an aggregated industry headline. Read the full story at Drug Channels

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Pharma companies have been part of the global economy and health systems for centuries. Now, as drugmakers pla…
Jun 22, 2026
Sanofi's R&D chief Ashrafian to hit the exit as new CEO seeks to fix stuttering pipeline with Roche alum
The WeekFierceBiotech ↗
Recently appointed Sanofi CEO Belén Garijo has stamped her mark on the organization, hiring Paulo Fontoura, M.…
Jun 22, 2026
Eli Lilly Halts 340B Discounts for Noncompliant Hospitals
The WeekBriefing
The move follows a June 8 deadline set for hospitals that failed to provide claims data required under Lilly’s…
Jun 22, 2026